The optimal strategy for NSCLC patients with tumor PD-L1 expression <50% has to be better defined: potential candidate therapies include concomitant treatments with chemotherapy, a combination of immune checkpoint inhibitors, or sequential strategies. This evidence concerns the gene CD274 and non-small cell lung carcinoma.